［1］Gao C， Wang Y， Tian W， et al. The therapeutic significance of aromatase inhibitors in endometrial carcinoma［J］. Gynecol Oncol， 2014， 134（1）: 190-195.

［2］Franik S， Eltrop SM， Kremer JA， et al. Aromatase inhibitors （letrozole） for subfertile women with polycystic ovary syndrome［J］.Cochrane Database Syst Rev， 2018， 5（5）: Cd010287.

［3］Hamadeh IS， Patel JN， Rusin S， et al. Personalizing aromatase inhibitor therapy in patients with breast cancer［J］. Cancer Treat Rev，2018， 70: 47-55.

［4］Bhattacharjee D， Kumari KM， Avin S， et al. The evolutionary tale and future directions of aromatase inhibitors in breast carcinoma［J］. Anticancer Agents Med Chem， 2017， 17（11）:1487-1499.

［5］Langdon SP， Gourley C， Gabra H， et al. Endocrine therapy in epithelial ovarian cancer［J］. Expert Rev Anticancer Ther， 2017， 17（2）: 109-117.

［6］Paleari L， Rutigliani M， Siri G， et al. Aromatase inhibitors as adjuvant treatment for ER/PgR positive stage Ⅰ endometrial carcinoma: a retrospective cohort study［J］. Int J Mol Sci， 2020， 21（6）: 2227-2235.

［7］Hirakawa H， Yokoyama Y， Yoshida H， et al. Inhibitory effects of aromatase inhibitor on estrogen receptorα positive ovarian cancer in mice［J］. J Ovarian Res， 2014， 7（1）: 4-11.

［8］Krásenská M. Treatment with aromatase inhibitors in postmenopausal women with breast cancer and the possibility of influencing side effects［J］. Klin Onkol， 2016， 29（Suppl 3）:S39-S49.

［9］Zhao F， Ren D， Shen G， et al. Toxicity of extended adjuvant endocrine with aromatase inhibitors in patients with postmenopausal breast cancer: a systemtic review and metaanalysis［J］. Crit Rev Oncol Hematol， 2020， 156: 103114.

［10］KhosrowKhavar F， Filion KB， Bouganim N， et al. Aromatase inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a populationbased cohort study［J］. Circulation， 2020， 141（7）:549-559.

［11］Van Sinderen ML， Steinberg GR， Jrgensen SB， et al. Effects of estrogens on adipokines and glucose homeostasis in female aromatase knockout mice［J］. PLoS One， 2015， 10（8）: e0136143.

［12］Hamood R， Hamood H， Merhasin I， et al. Diabetes after hormone therapy in breast cancer survivors: a casecohort study［J］. J Clin Oncol， 2018， 36（20）: 2061-2069.

［13］Gibb FW， Dixon JM， Clarke C， et al. Higher insulin resistance and adiposity in postmenopausal women with breast cancer treated with aromatase inhibitors［J］. J Clin Endocrinol Metab， 2019， 104（9）: 3670-3678.

［14］Zhao XB， Ren GS. Diabetes mellitus and prognosis in women with breast cancer: A systematic review and metaanalysis［J］.Medicine （Baltimore）， 2016， 95（49）: e5602.

［15］Kim HJ， Kim HS， Kim HR， et al. Characterization of metabolic syndrome risk factors and healthrelated behaviors in Korean patients with breast cancer by abdominal obesity status［J］. J Nurs Res， 2020， 28（2）: e74-e83.

［16］Ghafuri S， Ghaderi E， Fahami Y， et al. Epidemiologic study of type 2 diabetes mellitus and metabolic syndrome in rural population of kurdistan province， Iran， in 2011-2017［J］. Diabetes Metab Syndr， 2019， 13（3）: 1689-1697.

［17］Battelli MG， Bortolotti M， Polito L， et al. Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase［J］. Redox Biol， 2019， 21: 101070.

［18］MauvaisJarvis F， Clegg DJ， Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis［J］. Endocr Rev， 2013， 34（3）: 309-338.

［19］López M， TenaSempere M. Estrogens and the control of energy homeostasis: a brain perspective［J］. Trends Endocrinol Metab， 2015， 26（8）: 411-421.

［20］Fontana R， Della Torre S， Meda C， et al. Estrogen replacement therapy regulation of energy metabolism in female mouse hypothalamus［J］. Endocrinology， 2014， 155（6）: 2213-2221.

［21］Camporez JP， Lyu K， Goldberg EL， et al. Antiinflammatory effects of oestrogen mediate the sexual dimorphic response to lipidinduced insulin resistance［J］. J Physiol， 2019， 597（15）: 3885-3903.

［22］Yuchi Y， Cai Y， Legein B， et al. Estrogen receptor α regulates βcell formation during pancreas development and following injury［J］. Diabetes， 2015， 64（9）: 3218-3228.

［23］Zhou Z， Ribas V， Rajbhandari P， et al. Estrogen receptor α protects pancreatic βcells from apoptosis by preserving mitochondrial function and suppressing endoplasmic reticulum stress［J］. J Biol Chem， 2018， 293（13）: 4735-4751.

［24］Vogel H， Mirhashemi F， Liehl B， et al. Estrogen deficiency aggravates insulin resistance and induces βcell loss and diabetes in female New Zealand obese mice［J］. Horm Metab Res， 2013， 45（6）: 430-435.

［25］Zhu L， Brown WC， Cai Q， et al. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathwayselective insulin resistance［J］. Diabetes， 2013， 62（2）: 424-434.

［26］Zhu L， Martinez MN， Emfinger CH， et al. Estrogen signaling prevents dietinduced hepatic insulin resistance in male mice with obesity［J］. Am J Physiol Endocrinol Metab， 2014， 306（10）: E1188-E1197.

［27］Kamble PG， Pereira MJ， Almby K， et al. Estrogen interacts with glucocorticoids in the regulation of lipocalin 2 expression in human adipose tissue. Reciprocal roles of estrogen receptor α and β in insulin resistance?［J］. Mol Cell Endocrinol， 2019， 490: 28-36.

［28］Lapauw B， T'Sjoen G， Mahmoud A， et al. Shortterm aromatase inhibition: effects on glucose metabolism and serum leptin levels in young and elderly men［J］. Eur J Endocrinol， 2009， 160（3）: 397-402.

［29］Matthews KA， Abrams B， Crawford S， et al. Body mass index in midlife women: relative influence of menopause， hormone use， and ethnicity［J］. Int J Obes Relat Metab Disord， 2001， 25（6）: 863-873.

［30］Stubbins RE， Najjar K， Holcomb VB， et al. Oestrogen alters adipocyte biology and protects female mice from adipocyte inflammation and insulin resistance［J］. Diabetes Obes Metab， 2012， 14（1）: 58-66.

［31］Adeyanju OA， Soetan OA， Soladoye AO， et al. Oral hormonal therapy with ethinylestradiollevonorgestrel improves insulin resistance， obesity， and glycogen synthase kinase3 independent of circulating mineralocorticoid in estrogendeficient rats［J］. Can J Physiol Pharmacol， 2018， 96（6）: 577-586.

［32］Luo F， Huang WY， Guo Y， et al. 17βestradiol lowers triglycerides in adipocytes via estrogen receptor α and it may be attenuated by inflammation［J］. Lipids Health Dis， 2017， 16（1）: 182-187.

［33］Luo F， Guo Y， Ruan GY， et al. Estrogen lowers triglyceride via regulating hepatic APOA5 expression［J］. Lipids Health Dis， 2017， 16（1）: 72-74.

［34］Pfeiler G， Knigsberg R， Hadji P， et al. Impact of body mass index on estradiol depletion by aromatase inhibitors in postmenopausal women with early breast cancer［J］. Br J Cancer， 2013， 109（6）: 1522-1527.

［35］Lovejoy JC， Champagne CM， de Jonge L， et al. Increased visceral fat and decreased energy expenditure during the menopausal transition［J］. Int J Obes （Lond）， 2008， 32（6）: 949-958.

［36］Goh VHH， Hart WG. Excess fat in the abdomen but not general obesity is associated with poorer metabolic and cardiovascular health in premenopausal and postmenopausal Asian women［J］. Maturitas， 2018， 107: 33-38.

［37］Bhardwaj P， Ikeda T， Zhou XK， et al. Supplemental estrogen and caloric restriction reduce obesityinduced periprostatic white adipose inflammation in mice［J］. Carcinogenesis， 2019， 40（7）: 914-923.

［38］Bracht JR， VieiraPotter VJ， De Souza Santos R， et al. The role of estrogens in the adipose tissue milieu［J］. Ann N Y Acad Sci， 2020， 1461（1）: 127-143.

［39］Mu PW， Jiang P， Wang MM， et al. Oestrogen exerts antiinflammation via p38 MAPK/NFκB cascade in adipocytes［J］. Obes Res Clin Pract， 2016， 10（6）: 633-641.

［40］Gravena AA， Brischiliari SC， Lopes TC， et al. Excess weight and abdominal obesity in postmenopausal Brazilian women: a populationbased study［J］. BMC Womens Health， 2013， 13: 46-52.

［41］Lizcano F， Guzmán G. Estrogen deficiency and the origin of obesity during menopause［J］. Biomed Res Int， 2014， 2014: 757461.

［42］Paternoster S， Falasca M. The intricate relationship between diabetes， obesity and pancreatic cancer［J］. Biochim Biophys Acta Rev Cancer， 2020， 1873（1）: 188326.

［43］Kabat GC， Kim MY， Stefanick M， et al. Metabolic obesity phenotypes and risk of colorectal cancer in postmenopausal women［J］. Int J Cancer， 2018， 143（3）: 543-551.

［44］Liu Y， Metzinger MN， Lewellen KA， et al. Obesity contributes to ovarian cancer metastatic success through increased lipogenesis， enhanced vascularity， and decreased infiltration of M1 macrophages［J］. Cancer Res， 2015， 75（23）: 5046-5057.

［45］Maliniak ML， Patel AV， McCullough ML， et al. Obesity， physical activity， and breast cancer survival among older breast cancer survivors in the Cancer Prevention StudyⅡ Nutrition Cohort［J］. Breast Cancer Res Treat， 2018， 167（1）: 133-145.

［46］He JY， Wei XH， Li SJ， et al. Adipocytederived IL6 and leptin promote breast cancer metastasis via upregulation of Lysyl Hydroxylase2 expression［J］. Cell Commun Signal， 2018， 16（1）: 100.

［47］Zahid H， Subbaramaiah K， Iyengar NM， et al. Leptin regulation of the p53HIF1α/PKM2aromatase axis in breast adipose stromal cells: a novel mechanism for the obesitybreast cancer link［J］. Int J Obes （Lond）， 2018， 42（4）: 711-720.

［48］Kim HG， Jin SW， Kim YA， et al. Leptin induces CREBdependent aromatase activation through COX2 expression in breast cancer cells［J］. Food Chem Toxicol， 2017， 106（Pt A）: 232-241.

［49］Park SM， Kwak YS， Ji JG. The effects of combined exercise on healthrelated fitness， endotoxin， and immune function of postmenopausal women with abdominal besity［J］. J Immunol Res， 2015， 2015: 830567.

［50］Ha MS， Son WM. Combined exercise is a modality for improving insulin resistance and agingrelated hormone biomarkers in elderly Korean women［J］. Exp Gerontol， 2018， 114: 13-18.

［51］Giles ED， Jindal S， Wellberg EA， et al. Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer［J］. Breast Cancer Res， 2018， 20（1）: 50-63.